Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients.
Gibney G, Elfiky A, Hoimes C, Burns A, Rowen E, McDonough J, Lampert R, Gross C, Kelly W. Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients. Journal Of Clinical Oncology 2010, 28: tps244-tps244. DOI: 10.1200/jco.2010.28.15_suppl.tps244.Peer-Reviewed Original Research